Effects of sympathetic nerves and angiotensin II on renal sodium and water handling in rats with common bile duct ligature.
We tested the hypothesis that angiotensin II is likely to be mandatory for the neurogenic sodium and volume retention in cirrhotic rats with common bile duct ligature (BDL) following an acute volume load. To assess the neural control of volume homeostasis, 21 days after common BDL rats underwent volume expansion (0.9% NaCL; 10% body wt over 30 min) to decrease renal sympathetic nerve activity. Untreated animals, rats with renal denervation or pretreated with a nonhypotensive dose of an angiotensin II type 1 receptor antagonist were studied. The renal renin-angiotensin system was assessed by immunohistochemistry and RT-PCR. Rats with BDL excreted only 71 +/- 4% of the administered volume load. In cirrhotic rats pretreated with an angiotensin II AT1 inhibitor or after renal denervation, these values ranged significantly higher from 98 to 103% (P < 0.05 for all comparisons). Renal sympathetic nerve activity decreases by volume expansion were impaired in BDL rats (P < 0.05) but unaffected by angiotensin II receptor inhibition. In kidneys of BDL animals, renin mRNA was increased, and immunohistochemistry revealed increased staining for peritubular angiotensin II. Renal denervation in BDL animals reduced renin expression within 5 days to control levels. In conclusion, the impaired excretion of an acute volume load in rats with liver cirrhosis is due to effects of an increased renal sympathetic nerve activity that are likely to be dependent on intrarenal angiotensin II and renin. We speculate that similar changes may contribute to long-term volume retention in liver cirrhosis.
Veelken
Roland
R
Dept. of Medicine IV, Univ. of Erlangen-Nürnberg, Loschgestrasse 8, 91054 Erlangen, Germany. Roland.Veelken@rzmail.uni-erlangen.de
Hilgers
Karl F
KF
Porst
Markus
M
Krause
Holger
H
Hartner
Andrea
A
Schmieder
Roland E
RE
D000804:Angiotensin II / Q000494:pharmacology*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D001835:Body Weight; D003135:Common Bile Duct; D004305:Dose-Response Relationship, Drug; D008026:Ligation; D008103:Liver Cirrhosis / Q000378:metabolism* / Q000503:physiopathology*; D008297:Male; D009287:Naphthyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D012083:Renin / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000502:physiology; D012964:Sodium / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000502:physiology*; D014662:Vasoconstrictor Agents / Q000494:pharmacology*; D014867:Water / Q000378:metabolism
D047228:Angiotensin II Type 1 Receptor Blockers; D009287:Naphthyridines; D044140:Receptor, Angiotensin, Type 1; D014662:Vasoconstrictor Agents; C095905:ZD 7155; D014867:Water; D000804:Angiotensin II; D012964:Sodium; D012083:Renin